Glutamatergic agents for schizophrenia: current evidence and perspectives.

Glutamatergic agents for schizophrenia: current evidence and perspectives.

Item
http://www.wikidata.org/entity/Q38444551
Treating Negative Symptoms in Schizophrenia: an UpdateEffects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategyN100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth.Investigational dopamine antagonists for the treatment of schizophrenia.Heritability and Familiality of Temperament and Character Dimensions in Korean Families with Schizophrenic Linkage Disequilibrium.Drugs, games, and devices for enhancing cognition: implications for work and society.Ionotropic glutamate receptors: Which ones, when, and where in the mammalian neocortex.Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.Ascorbic Acid to Manage Psychiatric Disorders.
P2860

Glutamatergic agents for schizophrenia: current evidence and perspectives.

Item
http://www.wikidata.org/entity/Q38444551
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Glutamatergic agents for schizophrenia: current evidence and perspectives.
@en
type
label
Glutamatergic agents for schizophrenia: current evidence and perspectives.
@en
prefLabel
Glutamatergic agents for schizophrenia: current evidence and perspectives.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Glutamatergic agents for schizophrenia: current evidence and perspectives.
@en
P2093
P2860
P304
P31
P356
10.1586/17512433.2015.1040393
P407
P433
P478
P577
P698
P921